Journal
BREAST CANCER RESEARCH
Volume 23, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13058-021-01389-9
Keywords
miR-3613-3p; Tumor suppressor; Tumor biomarker; Cancer cell proliferation; Cancer stem cell; Cell cycle
Categories
Funding
- National Natural Science Foundation of China (NSFC) [81972795, 81672914]
- Bilateral Inter-Governmental S&T Cooperation Project from Ministry of Science and Technology of China [2018YFE0114300]
Ask authors/readers for more resources
Our study identified a frequent deletion of MIR3613 in the breast cancer genome, which was correlated with molecular subtypes and poor prognosis in estrogen receptor-positive patients. MiR-3613-3p levels were significantly lower in tumor tissues or serum of breast cancer patients. Functional studies showed that miR-3613-3p could inhibit proliferation, promote apoptosis, and suppress tumor growth and metastasis. Additionally, miR-3613-3p may regulate the cell cycle by targeting SMS, PAFAH1B2, or PDK3 to restrain tumor progression, indicating a potential marker or treatment for breast cancer patients.
Background MicroRNAs have been reported to participate in tumorigenesis, treatment resistance, and tumor metastasis. Novel microRNAs need to be identified and investigated to guide the clinical prognosis or therapy for breast cancer. Method The copy number variations (CNVs) of MIR3613 from Cancer Genome Atlas (TCGA) or Cancer Cell Line Encyclopedia (CCLE) were analyzed, and its correlation with breast cancer subtypes or prognosis was investigated. The expression level of miR-3613-3p in tumor tissues or serum of breast cancer patients was detected using in situ hybridization and qPCR. Gain-of-function studies were performed to determine the regulatory role of miR-3613-3p on proliferation, apoptosis, and tumor sphere formation of human breast cancer cells MDA-MB-231 or MCF-7. The effects of miR-3613-3p on tumor growth or metastasis in an immunocompromised mouse model of MDA-MB-231-luciferase were explored by intratumor injection of miR-3613-3p analogue. The target genes, interactive lncRNAs, and related signaling pathways of miR-3613-3p were identified by bioinformatic prediction and 3 '-UTR assays. Results We found that MIR3613 was frequently deleted in breast cancer genome and its deletion was correlated with the molecular typing, and an unfavorable prognosis in estrogen receptor-positive patients. MiR-3613-3p level was also dramatically lower in tumor tissues or serum of breast cancer patients. Gain-of-function studies revealed that miR-3613-3p could suppress proliferation and sphere formation and promote apoptosis in vitro and impeded tumor growth and metastasis in vivo. Additionally, miR-3613-3p might regulate cell cycle by targeting SMS, PAFAH1B2, or PDK3 to restrain tumor progression. Conclusion Our findings indicate a suppressive role of miR-3613-3p in breast cancer progression, which may provide an innovative marker or treatment for breast cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available